Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group
- PMID: 9619760
- DOI: 10.1007/s002800050786
Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group
Abstract
Purpose: Tomudex is a second-generation folate analogue that when polyglutamated is a potent inhibitor of thymidylate synthase (TS).
Methods: Based on indications of antitumor activity in phase I trials, the Gynecologic Oncology Group initiated a phase II study of Tomudex 3 mg/m2 intravenously every 3 weeks in patients with epithelial ovarian cancer, who had been pretreated with platinum drugs, and had subsequently recurred more than 6 months following such treatment.
Results: Of 30 patients entered into the trial, 2 were pathologically ineligible, leaving 28 fully evaluable. In this patient population, Tomudex was generally well tolerated, but only three objective (partial) responses were documented.
Conclusions: With the level of activity seen, the drug was not considered for further clinical development in ovarian cancer by the Gynecologic Oncology Group. However, it may be worthwhile to explore whether quantitation of TS could lead to selection of patients more likely to respond to this TS inhibitor.
Similar articles
-
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.J Clin Oncol. 1996 Mar;14(3):716-21. doi: 10.1200/JCO.1996.14.3.716. J Clin Oncol. 1996. PMID: 8622016 Clinical Trial.
-
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.Ann Oncol. 1996 Feb;7(2):179-82. doi: 10.1093/oxfordjournals.annonc.a010546. Ann Oncol. 1996. PMID: 8777175 Clinical Trial.
-
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.Br J Cancer. 1996 Aug;74(3):479-81. doi: 10.1038/bjc.1996.386. Br J Cancer. 1996. PMID: 8695369 Free PMC article. Clinical Trial.
-
Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.Invest New Drugs. 1996;14(3):305-16. doi: 10.1007/BF00194534. Invest New Drugs. 1996. PMID: 8958186 Review.
-
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.Eur J Cancer. 1995 Jul-Aug;31A(7-8):1277-82. doi: 10.1016/0959-8049(95)00166-g. Eur J Cancer. 1995. PMID: 7577036 Review.
Cited by
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17. Gynecol Oncol. 2011. PMID: 21414654 Free PMC article. Clinical Trial.
-
A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies.Br J Cancer. 2005 Oct 17;93(8):868-75. doi: 10.1038/sj.bjc.6602811. Br J Cancer. 2005. PMID: 16222320 Free PMC article. Clinical Trial.
-
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.Invest New Drugs. 2006 Jan;24(1):37-77. doi: 10.1007/s10637-005-4541-1. Invest New Drugs. 2006. PMID: 16380836 Review. No abstract available.
-
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
